martes, 17 de marzo de 2015

The clinical pharmacogenetics implementation consortium guideline f... - PubMed - NCBI

The clinical pharmacogenetics implementation consortium guideline f... - PubMed - NCBI



 2014 Oct;96(4):423-8. doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Abstract

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.

PMID:
 
24918167
 
[PubMed - indexed for MEDLINE] 
PMCID:
 
PMC4169720
 
Free PMC Article
-.-.-

full text from ► Clinical Pharmacogenetics Implementation Consortium

National Guideline Clearinghouse | The Clinical Pharmacogenetics Implementation Consortium guideline for <em>SLCO1B1</em> and simvastatin-induced myopathy: 2014 update.



Clinical Pharmacogenetics Implementation Consortium

National Guideline Clearinghouse (NGC)

Guideline Title
The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Bibliographic Source(s)
Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014 Oct;96(4):423-8. [37 references]PubMed External Web Site Policy
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M, Clinical Pharmacogenetics Implementation Consortium (CPIC). The Clinical Pharmacogenetics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112-7. [41 references]
This guideline meets NGC's 2013 (revised) inclusion criteria.

No hay comentarios: